Following a cyberattack last month that rocked its operations, Boston Scientific has issued a positive update as it continues an investigation of the incident.
Boston shared that it has seen “no indication of unauthorised activity” in its environment following the cyberattack that caused disruption on 25 August.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The medtech giant highlighted in a 5 September update that it has taken steps to contain the threat, strengthen its security measures and safely restore its systems.
All analyses to date indicate that the impact of the cybersecurity incident was isolated to select internal infrastructures, Boston stated, adding that cybersecurity experts remain “actively involved” in the investigation.
Elaborating on its recovery following the cyberattack, which Boston said at the time had hindered its ability to process and ship customer orders, the company said it is continuing to make “strong progress” in restoring its global operations.
The company highlighted that its distribution network has been “substantially restored”, and that its major distribution centres are now processing and shipping products “at or above” normal operating levels.
Teams are working around the clock to fulfil customer orders, reduce backlogs and accelerate the delivery of products to customers and the patients who depend on them, Boston stated.
It also shared that progress vis-à-vis restoration is also ongoing across its broader supply chain, with all sterilisation facilities once again operational and processing products, with manufacturing resumed across “most facilities globally”, with additional capabilities continuing to come online.
Summarising its aims as it inches towards full operational recovery, Boston’s update concluded that its priorities are centred on fulfilling customer orders, replenishing sales representative inventory and reduce remaining backlogs, alongside restoring all manufacturing capabilities, and maintaining the flow of products across its global supply chain.
Upon discovery of the cyber breach, on 25 August Boston filed a Form 8-K with the US Securities and Exchange Commission (SEC), stating at the time that the “full scope, nature and impacts” of the incident, along with the ensuing operational and financial impacts of the incident, were yet to be determined.
Cyberattacks on medtech and related companies have proven a blight throughout 2026, with other affected industry players including Stryker and Intuitive in March.
Commenting at the time of Boston’s cyberattack in August, Dray Agha, senior manager of security operations at cybersecurity specialist Huntress, said: “The attack on Boston Scientific demonstrates that cyber incidents in the medtech sector extend far beyond IT and actively threaten the global healthcare supply chain.
“When a major manufacturer is paralysed and unable to process or ship medical orders, the disruption creates immediate ripple effects that can ultimately delay critical treatments and impact patient care down the line.”
